Literature DB >> 30341700

Chronic heart failure: a disease of the brain.

Ram B Singh1, Krasimira Hristova2, Jan Fedacko3, Galal El-Kilany4, Germaine Cornelissen5.   

Abstract

The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.

Entities:  

Keywords:  Brain-heart interactions; Cardiac failure; Hypertrophy of heart; Neurohumoral dysfunction

Mesh:

Substances:

Year:  2019        PMID: 30341700     DOI: 10.1007/s10741-018-9747-3

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  31 in total

1.  Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial.

Authors:  P A Carson; C M O'Connor; A B Miller; S Anderson; R Belkin; G W Neuberg; J H Wertheimer; D Frid; A Cropp; M Packer
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

Review 2.  Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?

Authors:  Monte S Willis; Cam Patterson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

Review 3.  The autonomic nervous system and heart failure.

Authors:  Viorel G Florea; Jay N Cohn
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

4.  Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.

Authors:  K M Yee; S D Pringle; A D Struthers
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

5.  Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).

Authors:  I B Wilkinson; C M McEniery; K H Bongaerts; H MacCallum; D J Webb; J R Cockcroft
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

Review 6.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 7.  Sympathetic nervous system activation in human heart failure: clinical implications of an updated model.

Authors:  John S Floras
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

8.  Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure.

Authors:  Grzegorz Dzida; Andrzej Prystupa; Patrycja Lachowska-Kotowska; Tobiasz Kadas; Piotr Kamieński; Elżbieta Kimak; Magdalena Hałabiś; Paweł Kiciński
Journal:  Ann Agric Environ Med       Date:  2013       Impact factor: 1.447

9.  The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.

Authors:  Peter Nordström; Dorota Religa; Anders Wimo; Bengt Winblad; Maria Eriksdotter
Journal:  Eur Heart J       Date:  2013-06-04       Impact factor: 29.983

Review 10.  Brain mechanisms of sympathetic activation in heart failure: Roles of the renin‑angiotensin system, nitric oxide and pro‑inflammatory cytokines (Review).

Authors:  Bin Xu; Hongli Li
Journal:  Mol Med Rep       Date:  2015-10-13       Impact factor: 2.952

View more
  6 in total

Review 1.  Sympathetic activation in congestive heart failure: an updated overview.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Murray D Esler
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

2.  Increased Renal Dysfunction, Apoptosis, and Fibrogenesis Through Sympathetic Hyperactivity After Focal Cerebral Infarction.

Authors:  Yingyuan Cai; Xiaowei Lu; Xi Cheng; Qiushi Lv; Gelin Xu; Xinfeng Liu
Journal:  Transl Stroke Res       Date:  2021-03-12       Impact factor: 6.800

Review 3.  High Exogenous Antioxidant, Restorative Treatment (Heart) for Prevention of the Six Stages of Heart Failure: The Heart Diet.

Authors:  Ram B Singh; Jan Fedacko; Dominik Pella; Ghizal Fatima; Galal Elkilany; Mahmood Moshiri; Krasimira Hristova; Patrik Jakabcin; Natalia Vaňova
Journal:  Antioxidants (Basel)       Date:  2022-07-27

4.  Resveratrol in the Hypothalamic Paraventricular Nucleus Attenuates Hypertension by Regulation of ROS and Neurotransmitters.

Authors:  Jie Qi; Li-Yan Fu; Kai-Li Liu; Rui-Juan Li; Jin-An Qiao; Xiao-Jing Yu; Jia-Yue Yu; Ying Li; Zhi-Peng Feng; Qiu-Yue Yi; Hong Jia; Hong-Li Gao; Hong Tan; Yu-Ming Kang
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

Review 5.  Mechanism of tonifying-kidney Chinese herbal medicine in the treatment of chronic heart failure.

Authors:  Lizhen Chen; Dayun Yu; Shuang Ling; Jin-Wen Xu
Journal:  Front Cardiovasc Med       Date:  2022-09-12

6.  Light Emitting Diode Therapy Protects against Myocardial Ischemia/Reperfusion Injury through Mitigating Neuroinflammation.

Authors:  Songyun Wang; Qinyu Luo; Hui Chen; Jingyu Huang; Xuemeng Li; Lin Wu; Binxun Li; Zhen Wang; Dongdong Zhao; Hong Jiang
Journal:  Oxid Med Cell Longev       Date:  2020-09-03       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.